BioAtla, Inc. (BCAB): Nasdaq/NYSE listing notice — BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10

BioAtla, Inc.

Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.
Company requested immediate review and stay by Listing Council; Nasdaq counsel refused, but company claims precedent exists for such stays.
If suspended, BCAB is expected to trade on OTC under same symbol, which may materially affect trading price and volume.
As of Feb 6, $1.25M principal remained outstanding under Pre-Paid Advance Agreements; SEPA prohibits share sales during suspension.
Company asserts Nasdaq improperly delayed compliance confirmation and secretly overturned long-standing reverse stock split policy.

item 3.01 item 7.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioAtla, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BioAtla, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to suspend the Company’s securities from Nasdaq (the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alterna

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-041367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.